Is Sotorasib effective at treating the disease?

Introduction: On May 28, 2021, the U.S. Food and Drug Administration granted accelerated approval to the RAS GTPase family inhibitor sotorasib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutations determined by FDA-approved testing and who have received at least one previous systemic therapy.

Can the generic version of Sotorasib also effectively treat diseases?

The generic version of Sotorasib has been approved and verified by relevant regulatory agencies to ensure its efficacy and safety. The generic version of the drug is basically the same as the original drug in terms of drug ingredients, mechanism of action, therapeutic effect, etc., so the generic version of Sotorasib can also effectively treat diseases.

Common generic versions of Sotorasib include Laos Lucius Pharmaceutical Factory version, Bangladesh Everest version, Laos ASEAN Pharmaceutical version, Laos Daxiong Pharmaceutical version, etc. The effectiveness of the generic version of Sotorasib needs to be confirmed through strict approval and verification processes. When choosing a generic drug, patients and doctors should consider whether it has been approved and verified by relevant regulatory agencies to ensure its efficacy and safety.

How much does the generic version of Sotorasib cost per box?

The price of the generic version of Sotorasib produced by Laos Lucius Pharmaceutical Factory is about 1560$-1900$ per box, and the price of the generic version of Sotorasib produced by Everest in Bangladesh is about 4000$-4500$ per box. The specifications of both generic drugs are 120mgx56 capsules per box. The prices of other versions of generic drugs are not clear yet, and the price of generic versions of Sotorasib may change due to market supply and demand, purchasing channels, manufacturers and other factors. It is recommended to consult a doctor and obtain professional advice before purchasing.

Efficacy of Sotorasib

In a multicenter, single-arm, open-label clinical trial involving patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations, efficacy was evaluated in 124 patients whose disease had progressed during or after at least one prior systemic therapy. Patients received 960 mg of Sotorasib orally daily until disease progression or unacceptable toxicity. The results of the study showed that the patient's objective response rate (ORR) was 36%, and the median duration of response was 10 months. The study showed that was good.